Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.339
-0.001 (-0.29%)
At close: Dec 5, 2025, 4:00 PM EST
0.333
-0.007 (-1.92%)
After-hours: Dec 5, 2025, 6:18 PM EST
Akari Therapeutics, Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 10.19 | 9.66 | 11.36 | 13.53 | 8.08 | 9.16 | |
| Research & Development | 2.98 | 6.98 | 5.45 | 9.56 | 9.13 | 8.82 | |
| Operating Expenses | 13.16 | 16.65 | 16.81 | 23.09 | 17.21 | 17.98 | |
| Operating Income | -13.16 | -16.65 | -16.81 | -23.09 | -17.21 | -17.98 | |
| Interest Expense | -0.35 | -0.24 | - | - | - | - | |
| Interest & Investment Income | 0 | 0.01 | 0.08 | 0.05 | 0.01 | 0.01 | |
| Currency Exchange Gain (Loss) | -0.13 | 0.01 | 0.14 | 0.45 | -0.19 | 0.35 | |
| Other Non Operating Income (Expenses) | 3.91 | 2.08 | 6.58 | 4.84 | -0.03 | 0.53 | |
| EBT Excluding Unusual Items | -9.73 | -14.8 | -10.01 | -17.75 | -17.42 | -17.08 | |
| Merger & Restructuring Charges | -0.98 | -5 | - | - | - | - | |
| Other Unusual Items | -0.97 | - | - | - | - | - | |
| Pretax Income | -16.86 | -19.79 | -10.01 | -17.75 | -17.42 | -17.08 | |
| Net Income | -15.77 | -19.79 | -10.01 | -17.75 | -17.42 | -17.08 | |
| Net Income to Common | -15.77 | -19.79 | -10.01 | -17.75 | -17.42 | -17.08 | |
| Shares Outstanding (Basic) | 28 | 12 | 5 | 3 | 2 | 2 | |
| Shares Outstanding (Diluted) | 28 | 12 | 5 | 3 | 2 | 2 | |
| Shares Change (YoY) | 238.34% | 144.03% | 56.79% | 45.46% | 35.87% | 72.53% | |
| EPS (Basic) | -0.57 | -1.66 | -2.04 | -5.69 | -8.12 | -10.81 | |
| EPS (Diluted) | -0.57 | -1.66 | -2.04 | -5.69 | -8.12 | -20.00 | |
| Free Cash Flow | -9.65 | -12.55 | -16.43 | -21.5 | -18.85 | -16.95 | |
| Free Cash Flow Per Share | -0.35 | -1.05 | -3.36 | -6.89 | -8.78 | -10.73 | |
| EBITDA | -13.15 | -16.63 | -16.8 | -23.08 | -17.21 | -17.97 | |
| D&A For EBITDA | 0.01 | 0.01 | 0 | 0 | 0 | 0.01 | |
| EBIT | -13.16 | -16.65 | -16.81 | -23.09 | -17.21 | -17.98 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.